A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
A phase 1/2 trial of Atirmociclib and Fulvestrant in advanced solid tumours, run by Pfizer, active and no longer recruiting.
Overview
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors is a phase 1/2 interventional study registered as NCT05262400 by Pfizer, with 235 participants enrolled, started 2022-03-14 and due to reach its primary completion in 2027-02-26. Interventions recorded: PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion and PF-07104091 + PF-07220060 + letrozole dose expansion.
Similar pages
not linked directly; found by shared links- TrialA Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Shares Atirmociclib, Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Shares Atirmociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSNV4818 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Shares Atirmociclib, Pfizer (incl. Seagen) and the tag pipeline.